Alkermes plc (NASDAQ:ALKS) Shares Bought by Diversified Trust Co

Diversified Trust Co grew its stake in shares of Alkermes plc (NASDAQ:ALKS) by 4.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 38,131 shares of the company’s stock after acquiring an additional 1,684 shares during the period. Diversified Trust Co’s holdings in Alkermes were worth $1,067,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of ALKS. Signaturefd LLC lifted its position in shares of Alkermes by 51.2% during the 2nd quarter. Signaturefd LLC now owns 1,417 shares of the company’s stock valued at $34,000 after acquiring an additional 480 shares during the period. Hexagon Capital Partners LLC lifted its position in shares of Alkermes by 3,841.0% during the 2nd quarter. Hexagon Capital Partners LLC now owns 1,537 shares of the company’s stock valued at $37,000 after acquiring an additional 1,498 shares during the period. GAMMA Investing LLC raised its position in shares of Alkermes by 44.4% during the 2nd quarter. GAMMA Investing LLC now owns 2,287 shares of the company’s stock worth $55,000 after purchasing an additional 703 shares during the last quarter. CWM LLC raised its position in shares of Alkermes by 36.7% during the 1st quarter. CWM LLC now owns 2,732 shares of the company’s stock worth $74,000 after purchasing an additional 733 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC acquired a new position in shares of Alkermes during the 2nd quarter worth approximately $116,000. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on ALKS shares. TD Cowen started coverage on Alkermes in a research report on Monday, June 17th. They set a “buy” rating and a $34.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and set a $48.00 price objective on shares of Alkermes in a research report on Monday, September 16th. JPMorgan Chase & Co. lifted their price objective on Alkermes from $31.00 to $32.00 and gave the stock a “neutral” rating in a research report on Thursday, July 25th. HC Wainwright lifted their price objective on Alkermes from $35.00 to $37.00 and gave the stock a “neutral” rating in a research report on Thursday, July 25th. Finally, Robert W. Baird lifted their price objective on Alkermes from $37.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $36.70.

Alkermes Trading Down 2.4 %

Shares of Alkermes stock opened at $27.11 on Wednesday. The firm has a market cap of $4.59 billion, a PE ratio of 10.72, a P/E/G ratio of 0.59 and a beta of 0.46. The company has a quick ratio of 2.61, a current ratio of 2.99 and a debt-to-equity ratio of 0.22. The business’s fifty day moving average is $27.60 and its two-hundred day moving average is $25.76. Alkermes plc has a fifty-two week low of $22.01 and a fifty-two week high of $32.88.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Wednesday, July 24th. The company reported $0.70 EPS for the quarter, hitting analysts’ consensus estimates of $0.70. The business had revenue of $399.13 million during the quarter, compared to the consensus estimate of $393.30 million. Alkermes had a return on equity of 23.20% and a net margin of 19.15%. The business’s revenue for the quarter was down 35.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.38 EPS. Analysts anticipate that Alkermes plc will post 2.36 earnings per share for the current year.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.